AstraZeneca’s Imfinzi (durvalumab) Receives EC’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

 AstraZeneca’s Imfinzi (durvalumab) Receives EC’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

AstraZeneca’s Imfinzi (durvalumab) Receives EC’s Approval as 1L Treatment for Extensive-Stage Small Cell Lung Cancer

Shots:

  • The approval is based on P III CASPIAN study assessing Imfinzi + etoposide and either carboplatin/ cisplatin CT or Imfinzi + CT + tremelimumab vs PBO in 805 patients with ES-SCLC in 200 centers across 23 countries. The approval follows the CHMP’s positive opinion received in July’2020
  • Results: the study met its 1EPs of OS (13.0 vs 10.3mos.); ORR (68% vs 58%); 27% reduction in risk of death with delay in time for disease symptoms to worsen. Updated analysis: m-OS (12.9 vs 10.5 mos.); safety & tolerability is consistent with a known safety profile
  • Imfinzi is a mAb targeting PD-L1 and blocks PD-L1 interaction with PD-1 and CD80, currently being evaluated as monothx. and in combination with tremelimumab for multiple cancer indications and in P-III ADRIATIC trial for patients with limited-stage SCLC

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Los Angeles Times

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post